Jun Matsubayashi

Jun Matsubayashi

Auto-generated profile, based on publicly available information

Jun Matsubayashi

Department of Anatomic Pathology, Tokyo Medical University, Tokyo 160-8402, Japan

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2019 in Histopathology
Verified
Journal Article
Closed access
PDF file
MNMasato Nakaguro
Masato Nakaguro
MUMakoto Urano
Makoto Urano
IOIkuko Ogawa
Ikuko Ogawa
HHHideaki Hirai
Hideaki Hirai
YYYoshinari Yamamoto
Yoshinari Yamamoto
Toshitaka NagaoToshitaka Nagao
Toshitaka Nagao

6 August 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
CWChangshan Wang
Changshan Wang
MOMotohiko Oshima
Motohiko Oshima
DSDaisuke Sato
Daisuke Sato
HMHirotaka Matsui
Hirotaka Matsui
SKSho Kubota
Sho Kubota
GSGoro Sashida
Goro Sashida
Early T cell precursor acute lymphoblastic leukemia (ETP-ALL) is a new pathological entity with poor outcomes in T cell ALL (T-ALL) that is characterized by a high incidence of loss-of-function mutations in polycomb repressive complex 2 (PRC2) genes. We generated a mouse model of ETP-ALL by deleting Ezh2, one of the PRC2 genes, in p53-null hematopoietic cells. The loss of Ezh2 in p53-null hematopoietic cells impeded the differentiation of ETPs and eventually induced ETP-ALL–like disease in mice, indicating that PRC2 functions as a bona fide tumor suppressor in ETPs. A large portion of PRC2 target genes acquired DNA hypermethylation of their promoters following reductions in H3K27me3 levels upon the loss of Ezh2, which included pivotal T cell differentiation–regulating genes. The reactivation of a set of regulators by a DNA-demethylating agent, but not the transduction of single regulator genes, effectively induced the differentiation of ETP-ALL cells. Thus, PRC2 protects key T cell developmental regulators from DNA hypermethylation in order to keep them primed for activation upon subsequent differentiation phases, while its insufficiency predisposes ETPs to leukemic transformation. These results revealed a previously unrecognized epigenetic switch in response to PRC2 dysfunction and provide the basis for specific rational epigenetic therapy for ETP-ALL with PRC2 insufficiency.

1 November 2018 in Lung Cancer
Verified
Journal Article
Closed access
DEDaisuke Eriguchi
Daisuke Eriguchi
YSYoshihisa Shimada
Yoshihisa Shimada
KIKentaro Imai
Kentaro Imai
HFHideyuki Furumoto
Hideyuki Furumoto
TOTetsuya Okano
Tetsuya Okano
NINorihiko Ikeda
Norihiko Ikeda

22 January 2016 in BMC Cancer
Verified
Journal Article
Open access
PDF file
Jiro AkimotoJiro Akimoto
Jiro Akimoto
HFHirokazu Fukuhara
Hirokazu Fukuhara
TSTomohiro Suda
Tomohiro Suda
KNKenta Nagai
Kenta Nagai
MIMegumi Ichikawa
Megumi Ichikawa
TNToshitaka Nagao
Toshitaka Nagao
A neuroendocrine tumor (NET) can develop anywhere in the body, but is mainly found in the pancreas, gastrointestinal tract, and lungs. This report is a retrospective study of the clinicopathological features of NET patients with brain metastasis whose tissue diagnosis was made at our hospital. Patients with brain metastasis evidenced by clinical records and images were accumulated among 302 patients in whom tissue diagnosis of NETs was made at our hospital between 2008 and 2013. In the patients, the primary lesion, pathological classification, pattern of metastasis, details of treatment, and outcomes were analyzed. Brain metastasis was observed in 31 patients (10.3 %). The primary lesion was in the lungs in 26 patients (83.9 %), and the mammary glands, esophagus, and uterus in 1 patient each. Primary lesions were unknown in 2 patients, including 1 patient in whom NETs were detected in the lymph nodes alone. Pathological classification of the primary lesion was NET Grade 2 (Ki-67: 3 to 20 %) in 3 patients and neuroendocrine carcinoma (NEC, Ki-67: ≥21 %) in 26 patients. The median period from onset of the primary lesion up to diagnosis of brain metastasis was 12.8 months, and the brain lesion preceded brain metastasis in 6 patients. Ten patients had a single metastasis whereas 21 patients had multiple metastases, but no characteristics were observed in their images. Brain metastasis was extirpated in 10 patients. Stereotactic radiotherapy alone was administered in 6 patients, and brain metastasis was favorably controlled in most of the patients with coadministration of cranial irradiation as appropriate. The median survival period from diagnosis of brain metastasis was 8.1 months, and the major cause of death was aggravation of the primary lesion or metastatic lesions in other organs. Most of NET patients with brain metastasis showed the primary lesion of NEC in the lungs, and they had multiple metastases to the liver, lymph nodes, bones, and so forth at the time of diagnosis of brain metastasis. The guidelines for accurate diagnosis and treatment of NETs should be immediately established based on further analyses of NET patients with brain metastasis.

29 July 2008 in The Journal of Pathology
Verified
Journal Article
Open access
PDF file
JMJ Matsubayashi
J Matsubayashi
MTM Takanashi
M Takanashi
KOK Oikawa
K Oikawa
KFKoji Fujita
Koji Fujita
MTM Tanaka
M Tanaka
KMK Mukai
K Mukai
G‐protein‐coupled receptor kinases (GRKs) comprise a family of seven mammalian serine/threonine protein kinases that phosphorylate and regulate agonist‐bound, activated, G‐protein‐coupled receptors (GPCRs). GRKs and β‐arrestins are key participants in the canonical pathways leading to phosphorylation‐dependent GPCR desensitization, endocytosis, intracellular trafficking and resensitization. Here we show that GRK4 isoforms are expressed in human breast cancer but not in normal epithelia. In addition, GRK4‐over‐expressing cells activated the mitogen‐activated protein kinase (MAPK) mediated by ERK 1/2 and JNK phosphorylation in breast cancer‐derived cell lines. Furthermore, suppression of β‐arrestins decreased GRK4‐stimulated ERK 1/2 or JNK phosphorylations. These data indicate that high‐level expression of GRK4 may activate MAPK signalling pathways mediated by β‐arrestins in breast cancer cells, suggesting that GRK4 may be implicated in breast cancer carcinogenesis. Copyright © 2008 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

21 September 2010 in Medical Molecular Morphology
Verified
Journal Article
Closed access
PDF file
TSTakafumi Satomi
Takafumi Satomi
MWMasato Watanabe
Masato Watanabe
JMJun Matsubayashi
Jun Matsubayashi
Toshitaka NagaoToshitaka Nagao
Toshitaka Nagao
HCHiroshige Chiba
Hiroshige Chiba